<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03558035</url>
  </required_header>
  <id_info>
    <org_study_id>LC2014L12</org_study_id>
    <nct_id>NCT03558035</nct_id>
  </id_info>
  <brief_title>New Strategy of Improving Treatment Outcome and Larynx-preservation Rate in Locally Advanced Hypopharyngeal Carcinoma</brief_title>
  <official_title>New Strategy of Improving Treatment Outcome and Larynx-preservation Rate in Locally Advanced Hypopharyngeal Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese Academy of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chinese Academy of Medical Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To develope stratification treatment for the patients who have locally advanced
      hypopharyngeal carcinoma. Experimental group patients were treated individually according to
      the response status after induction chemotherapy, receiving chemoradiotherapy or surgery.
      Thus to achieve a better survival rate and a higher larynx-preservation rate as well as a
      lower treatment related toxicity rate compared with standard treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Eligiblity patient were assign to induction chemotherapy plus concurrent chemotherapy group
      (IC +CCRT group, Arm A)and concurrent chemoradiotherapy group(CCRT group, Arm B). For
      patients in Arm A, treatment response were evaluated after 2cycles, if the response reached
      partial response/complete response, patients received concurrent chemoradiotherapy,
      otherwise, patients will received surgery and radiotherpay/concurrent chemoradiotherapy after
      surgery. For patients received concurrent chemoradiotherapy (both in Arm A and Arm B) ,
      treatment response were evaluated at 50 Gy. if response reached complete response or major
      partial response(&gt;80% tumor regression), patients will received radical chemoradiotherapy,
      otherwise, patients will received surgery.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2014</start_date>
  <completion_date type="Anticipated">August 2020</completion_date>
  <primary_completion_date type="Anticipated">August 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>overall survival</measure>
    <time_frame>5 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>disease free survival</measure>
    <time_frame>5 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>distant-metastasis free survival</measure>
    <time_frame>5 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>larynx-preservation rate</measure>
    <time_frame>5 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>treatment related toxicities</measure>
    <time_frame>2 year</time_frame>
    <description>hematology and surgery related complications</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">96</enrollment>
  <condition>Hypopharyngeal Cancer</condition>
  <arm_group>
    <arm_group_label>Induction chemotherapy and concurret chemoradiotherapy group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive 2 cycles of paclitaxel, cisplatin and 5-Fluorouracil chemotherapy followed by Surgery or Chemo-radiotherapy according to the response status after induction chemo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Concurrent chemoradiotherapy group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receive single-agent cisplatin chemotherapy concurrent with Radiotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Induction CT+ CRT group</intervention_name>
    <description>Induction CT: Paclitaxel 175mg/m2 IV on d1 and d22, cisplatin 75mg/m2 IV on d1 and d22, 5-Fluorouracil 750mg/m2 IV continuously on d1-4 and d22-25, CRT: cisplatin 80mg/m2 IV on d1 of each 21 days cycle and 70 Gy radiotherapy</description>
    <arm_group_label>Induction chemotherapy and concurret chemoradiotherapy group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Concurrent CRT group</intervention_name>
    <description>cisplatin 100mg/m2 IV on d1 of each 21 days cycle and 70 Gy radiotherapy</description>
    <arm_group_label>Concurrent chemoradiotherapy group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically proven squamous cell carcinoma of hypopharynx

          -  Stage III/IV M0, with T3/4 N0-3 or T1-4 N2-3

          -  Karnofsky Performance Status&gt;=70

          -  Have measurable lesions on CT/MRI

          -  Treatment for the first time

          -  Expected lifetime &gt; 6 months

          -  Normal blood test, hepatic and renal functions

          -  Normal hearing

          -  Can understand and sign the consent

          -  Have follow up condition

        Exclusion Criteria:

          -  Past malignancies history (except for stage I non-melanoma skin cancer or cervical
             carcinoma in situ)

          -  Previously treatment for cancer

          -  Pregnant or breeding woman, female without contraception

          -  Enrolling in other drug trials

          -  Severe comorbidities including myocardial infarction, arrhythmia, cerebral vascular
             disease, ulceration disease, mental disease and uncontrolled diabetes

          -  Without follow up

          -  Receive target therapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Junlin Yi, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>CAMS</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Junlin Yi, Professor</last_name>
    <phone>0086013661217998</phone>
    <email>yijunlin1969@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cancer hospital, Chinese Academy of Medical Sciences</name>
      <address>
        <city>Beijing</city>
        <zip>100021</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Junlin YI, MD</last_name>
      <phone>861087788504</phone>
      <email>junlinyi@sohu.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Blanchard P, Baujat B, Holostenco V, Bourredjem A, Baey C, Bourhis J, Pignon JP; MACH-CH Collaborative group. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): a comprehensive analysis by tumour site. Radiother Oncol. 2011 Jul;100(1):33-40. doi: 10.1016/j.radonc.2011.05.036. Epub 2011 Jun 16.</citation>
    <PMID>21684027</PMID>
  </reference>
  <reference>
    <citation>Blanchard P, Bourhis J, Lacas B, Posner MR, Vermorken JB, Cruz Hernandez JJ, Bourredjem A, Calais G, Paccagnella A, Hitt R, Pignon JP; Meta-Analysis of Chemotherapy in Head and Neck Cancer, Induction Project, Collaborative Group. Taxane-cisplatin-fluorouracil as induction chemotherapy in locally advanced head and neck cancers: an individual patient data meta-analysis of the meta-analysis of chemotherapy in head and neck cancer group. J Clin Oncol. 2013 Aug 10;31(23):2854-60. doi: 10.1200/JCO.2012.47.7802. Epub 2013 Jul 8.</citation>
    <PMID>23835714</PMID>
  </reference>
  <reference>
    <citation>Pointreau Y, Garaud P, Chapet S, Sire C, Tuchais C, Tortochaux J, Faivre S, Guerrif S, Alfonsi M, Calais G. Randomized trial of induction chemotherapy with cisplatin and 5-fluorouracil with or without docetaxel for larynx preservation. J Natl Cancer Inst. 2009 Apr 1;101(7):498-506. doi: 10.1093/jnci/djp007. Epub 2009 Mar 24.</citation>
    <PMID>19318632</PMID>
  </reference>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>June 5, 2018</study_first_submitted>
  <study_first_submitted_qc>June 5, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 15, 2018</study_first_posted>
  <last_update_submitted>March 25, 2019</last_update_submitted>
  <last_update_submitted_qc>March 25, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 27, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese Academy of Medical Sciences</investigator_affiliation>
    <investigator_full_name>Li Gao</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Hypopharyngeal carcinoma</keyword>
  <keyword>Locally advanced</keyword>
  <keyword>Multi-disciplinary treatment</keyword>
  <keyword>Functional Magnetic Resonance Imaging</keyword>
  <keyword>Prognosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Hypopharyngeal Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

